Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Inmed Pharmaceuticals Inc (IMLFF)

Inmed Pharmaceuticals Inc (IMLFF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.30
Trade IMLFF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.0400 +18.75%
on 10/15/20
3.8164 -5.41%
on 10/14/20
+0.0400 (+1.12%)
since 09/25/20
3-Month
3.0400 +18.75%
on 10/15/20
5.8116 -37.88%
on 08/07/20
-0.5400 (-13.01%)
since 07/27/20
52-Week
3.0400 +18.75%
on 10/15/20
10.6260 -66.03%
on 01/21/20
-2.9537 (-45.00%)
since 10/25/19

Most Recent Stories

More News
InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

, /PRNewswire/ - ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way...

IN.TO : 4.74 (+7.48%)
IMLFF : 3.6100 (+6.20%)
InMed Pharmaceuticals Announces Additional IntegraSyn™ Patent Filing

, /PRNewswire/ -  ("InMed" or the "Company") (TSX:IN) (OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way...

IN.TO : 4.74 (+7.48%)
IMLFF : 3.6100 (+6.20%)
InMed Pharmaceuticals Announces Additional IntegraSyn™ Patent Filing

TSX:IN OTCQX:IMLFF

IN.TO : 4.74 (+7.48%)
IMLFF : 3.6100 (+6.20%)
InMed Pharmaceuticals Reports Full Year Fiscal 2020 Financial Results and Provides Business Update

, /PRNewswire/ - ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in...

IMLFF : 3.6100 (+6.20%)
InMed Pharmaceuticals Reports Full Year Fiscal 2020 Financial Results and Provides Business Update

VANCOUVER, BC , Sept. 8, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting...

IMLFF : 3.6100 (+6.20%)
IN.TO : 4.74 (+7.48%)
InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020

  , /PRNewswire/ -  ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading...

IN.TO : 4.74 (+7.48%)
IMLFF : 3.6100 (+6.20%)
InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020

TSX:IN OTCQX:IMLFF  

IN.TO : 4.74 (+7.48%)
IMLFF : 3.6100 (+6.20%)
InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System

, /PRNewswire/ - ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way...

IN.TO : 4.74 (+7.48%)
IMLFF : 3.6100 (+6.20%)
InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System

VANCOUVER, BC , June 24, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting...

IMLFF : 3.6100 (+6.20%)
IN.TO : 4.74 (+7.48%)
InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation

, /PRNewswire/ -  ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the...

IN.TO : 4.74 (+7.48%)
IMLFF : 3.6100 (+6.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

2nd Resistance Point 3.8300
1st Resistance Point 3.7200
Last Price 3.6100
1st Support Level 3.4000
2nd Support Level 3.1900

See More

52-Week High 10.6260
Fibonacci 61.8% 7.7281
Fibonacci 50% 6.8330
Fibonacci 38.2% 5.9379
Last Price 3.6100
52-Week Low 3.0400

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar